HER2-Negative Metastatic Breast Cancer
1 competing product in clinical development for HER2-Negative Metastatic Breast Cancer.
Pipeline by Phase
Phase 11
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Durvalumab + Eribulin | Eisai | Phase 1 | Completed | 29 |